Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants.
Kishnani PS, Goldenberg PC, DeArmey SL, Heller J, Benjamin D, Young S, Bali D, Smith SA, Li JS, Mandel H, Koeberl D, Rosenberg A, Chen YT.
Kishnani PS, et al.
Mol Genet Metab. 2010 Jan;99(1):26-33. doi: 10.1016/j.ymgme.2009.08.003.
Mol Genet Metab. 2010.
PMID: 19775921
Free PMC article.
Clinical Trial.